Origins of LRT
In 1998, Dr. Weinberg began working on the metabolic effects of local anesthetics and discovered that an infusion of lipid emulsion could protect against and correct local anesthetic cardiac toxicity.
In 2006, the first case of successful treatment using LipidRescue™ Therapy was published. Immediately thereafter, Dr. Weinberg began the website www.LipidRescue.org, which houses a repository of over 300 reported cases where LipidRescue Therapy was used successfully.
LRT is a repurposing of certain lipid emulsion products that are regulatorily approved as parenteral nutritional supplements. Today, LRT is used around the world to treat LAST without regulatory approval on an off-label basis. In 2015 the American Heart Association’s Advance Cardiovascular Life Support protocol listed LRT as the standard of care for the treatment of LAST. ResQ Pharma was created to ensure reliable, global use of LRT by attaining regulatory approval.
In 2006, Guy Weinberg, MD started the website www.Lipidrescue.org with the twin goals of informing practitioners about the use of LipidRescue Therapy (LRT) and saving lives without concern to financial benefit. The site currently fields thousands of visits each month from physicians and nurses seeking to share experiences and improve their knowledge about local systemic anesthetic toxicity and the lifesaving therapy of LRT.
There is clear demand among practitioners around the world for an LRT product that will ensure safe, rapid and consistent application more economically. The various off-label products are not purpose-designed and are not suitable for emergency use.
The intellectual property around LRT was initially owned by the University of Illinois as the employer Dr. Weinberg. In 2015, ResQ Pharma acquired the intellectual property.